<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>UNLABELLED: Primary central <z:mp ids='MP_0008912'>nervous</z:mp> system <z:hpo ids='HP_0002665'>lymphoma</z:hpo> is defined as an extranodal <z:hpo ids='HP_0002665'>lymphoma</z:hpo> arising in the central <z:mp ids='MP_0008912'>nervous</z:mp> system in the absence of <z:e sem="disease" ids="C0442893" disease_type="Disease or Syndrome" abbrv="">systemic disease</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Because of their rare occurrence among <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, optimal treatment could hardly be established </plain></SENT>
<SENT sid="2" pm="."><plain>AIMS: In this retrospective survey we analyzed the result of combined treatment (systemic and intrathecal chemotherapy followed by consolidation radiotherapy) in patients with primary or relapsed central <z:mp ids='MP_0008912'>nervous</z:mp> system <z:hpo ids='HP_0002665'>lymphomas</z:hpo> diagnosed and treated in our hematological department between 1998-2009 </plain></SENT>
<SENT sid="3" pm="."><plain>PATIENTS AND METHODS: During this period (mean follow-up of 13.2 months) from 427 patients with newly diagnosed non-Hodgkin's <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, 22 primary central <z:mp ids='MP_0008912'>nervous</z:mp> system <z:hpo ids='HP_0002665'>lymphoma</z:hpo> was diagnosed (5.15%, 16 cerebral and 6 spinal cord <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cases) </plain></SENT>
<SENT sid="4" pm="."><plain>Significant male predominance (14:8) was registered with an age distribution of 34-77 years (mean = 60.7, median = 64 years) </plain></SENT>
<SENT sid="5" pm="."><plain>No patients were immunocompromised </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> central <z:mp ids='MP_0008912'>nervous</z:mp> system <z:hpo ids='HP_0002665'>lymphoma</z:hpo> specimens taken with neurosurgical resection or stereotaxic biopsies were confirmed histopathologically </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> cerebral <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cases proved to be diffuse large B-cell of origin, while in epidural <z:hpo ids='HP_0002665'>lymphomas</z:hpo> low grade subtypes also occurred </plain></SENT>
<SENT sid="8" pm="."><plain>Epidural <z:hpo ids='HP_0002665'>lymphomas</z:hpo> were treated with local radiotherapy (30-40 Gy), except for patients with follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo> getting rituximab-containing polychemotherapy (R + CHOP regimen) before irradiation </plain></SENT>
<SENT sid="9" pm="."><plain>In cerebral <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (every patients had supratentorial localization) the following combined therapy protocol was used: up to three courses of high dose <z:chebi fb="0" ids="44185">methotrexate</z:chebi> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> MTX 3g/m 2 in a single dose for 4 hours lasting drop-infusion) were given at 4-week intervals, followed by leucovorin-rescue 24 hours after MTX infusion </plain></SENT>
<SENT sid="10" pm="."><plain>Intrathecal combination of <z:chebi fb="0" ids="44185">methotrexate</z:chebi>, <z:chebi fb="0" ids="16040">cytosin</z:chebi>-arabinosid and <z:chebi fb="0" ids="41879">dexamethasone</z:chebi> was given three times after <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> MTX infusion </plain></SENT>
<SENT sid="11" pm="."><plain>In complete response after chemotherapy (evaluated by cranial MRI or CT, PET/CT), whole-brain irradiation was used in a total dose of 30 Gy </plain></SENT>
<SENT sid="12" pm="."><plain>In case of partial response, boost irradiation for the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> bed was also given </plain></SENT>
<SENT sid="13" pm="."><plain>In relapse or resistant cases, salvage regimen was applied: <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> MTX course combined with high dose <z:chebi fb="0" ids="16040">cytosin</z:chebi>-arabinosid (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> Ara-C) 3g/m 2 /dose b.i.d. over 4 h c.i., repeated in three cycles every four weeks </plain></SENT>
<SENT sid="14" pm="."><plain>RESULTS: Complete remission has been achieved in 9 patients with cerebral and in 4 patients with spinal cord <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (13/22; 59.0%), however, one relapsed patient became resistant and later expired, despite salvage therapy </plain></SENT>
<SENT sid="15" pm="."><plain>Primarily 9 patients were not evaluable for response: 5 received only one or two <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> MTX because of side effects, 4 patients died due to progression of the disease </plain></SENT>
<SENT sid="16" pm="."><plain>Mean of the overall survival (OS) in cerebral <z:hpo ids='HP_0002665'>lymphoma</z:hpo> was 19.5 (3-46, median of 10) months, in epidural group 14.1 (2-76, median of 5) months, whilst mean time to progression (<z:chebi fb="1" ids="18284">TTP</z:chebi>) was 4.5 (2-6.5, median of 4 months) </plain></SENT>
<SENT sid="17" pm="."><plain>The 2-year survival for <z:hpo ids='HP_0000001'>all</z:hpo> patients was 50% </plain></SENT>
<SENT sid="18" pm="."><plain><z:hpo ids='HP_0011009'>Acute</z:hpo> toxicity of chemotherapy was usually hematological, moreover, in 8 patients <z:hpo ids='HP_0000082'>impaired renal function</z:hpo> and <z:hpo ids='HP_0100806'>sepsis</z:hpo> developed </plain></SENT>
<SENT sid="19" pm="."><plain>No serious adverse effect of radiotherapy could be detected </plain></SENT>
<SENT sid="20" pm="."><plain>CONCLUSION: In primary central <z:mp ids='MP_0008912'>nervous</z:mp> system <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, basic treatment <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> <z:chebi fb="0" ids="44185">methotrexate</z:chebi> together with intrathecal combination of <z:chebi fb="0" ids="44185">methotrexate</z:chebi> + <z:chebi fb="0" ids="16040">cytosin</z:chebi>-arabinosid + <z:chebi fb="0" ids="41879">dexamethasone</z:chebi> followed by whole-brain irradiation of at least 30 Gy could produce a medium response rate in our study </plain></SENT>
<SENT sid="21" pm="."><plain>In case of relapse or progression, other salvage regimens containing <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> Ara-C alternating with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> MTX could reduce the treatment failure, as well </plain></SENT>
<SENT sid="22" pm="."><plain>After therapy PET/CT was negative in five patients with prolonged disease-free survival </plain></SENT>
</text></document>